Omaveloxolone (SkyclarysTM) for patients with Friedreich's ataxia

Sharadha Dayalan Naidu; Albena T. Dinkova-Kostova

doi:10.1016/j.tips.2023.03.005

Omaveloxolone (Skyclarys^TM) for patients with Friedreich's ataxia

Sharadha Dayalan Naidu, Albena T. Dinkova-Kostova (Lead / Corresponding author)

Research output: Contribution to journal › Article › peer-review

27 Citations (Scopus)

182 Downloads (Pure)

Original language	English
Pages (from-to)	394-395
Number of pages	2
Journal	Trends in Pharmacological Sciences
Volume	44
Issue number	6
Early online date	2 May 2023
DOIs	https://doi.org/10.1016/j.tips.2023.03.005
Publication status	Published - Jun 2023

ASJC Scopus subject areas

Toxicology
Pharmacology

Access to Document

10.1016/j.tips.2023.03.005Licence: CC BY

Final published versionFinal published version, 547 KBLicence: CC BY

Cite this

@article{e8d1e4688ae94d2e9e9b23b37f589ed6,

title = "Omaveloxolone (SkyclarysTM) for patients with Friedreich's ataxia",

author = "\{Dayalan Naidu\}, Sharadha and Dinkova-Kostova, \{Albena T.\}",

note = "Funding Information: We thank the Medical Research Council ( MR/W023806/1 and MR/T014644/1 ), the Biotechnology and Biological Sciences Research Council and GlaxoSmithKline ( BB/T508111/1 , BB/X00029X/1 , and BB/T017546/1 ), Tenovus Scotland ( T19/30 and T22/08 ), Reata Pharmaceuticals, and Medical Research Scotland ( PHD-50477-2021 ) for supporting our research and the COST Action CA20121, supported by the European Cooperation in Science and Technology ( www.cost.eu ) ( https://benbedphar.org/about-benbedphar/). Copyright: {\textcopyright} 2023 The Authors. Published by Elsevier Ltd.",

year = "2023",

month = jun,

doi = "10.1016/j.tips.2023.03.005",

language = "English",

volume = "44",

pages = "394--395",

journal = "Trends in Pharmacological Sciences",

issn = "0165-6147",

publisher = "Elsevier",

number = "6",

}

TY - JOUR

T1 - Omaveloxolone (SkyclarysTM) for patients with Friedreich's ataxia

AU - Dayalan Naidu, Sharadha

AU - Dinkova-Kostova, Albena T.

N1 - Funding Information: We thank the Medical Research Council ( MR/W023806/1 and MR/T014644/1 ), the Biotechnology and Biological Sciences Research Council and GlaxoSmithKline ( BB/T508111/1 , BB/X00029X/1 , and BB/T017546/1 ), Tenovus Scotland ( T19/30 and T22/08 ), Reata Pharmaceuticals, and Medical Research Scotland ( PHD-50477-2021 ) for supporting our research and the COST Action CA20121, supported by the European Cooperation in Science and Technology ( www.cost.eu ) ( https://benbedphar.org/about-benbedphar/). Copyright: © 2023 The Authors. Published by Elsevier Ltd.

PY - 2023/6

Y1 - 2023/6

UR - https://www.scopus.com/pages/publications/85156246049

U2 - 10.1016/j.tips.2023.03.005

DO - 10.1016/j.tips.2023.03.005

M3 - Article

C2 - 37142519

AN - SCOPUS:85156246049

SN - 0165-6147

VL - 44

SP - 394

EP - 395

JO - Trends in Pharmacological Sciences

JF - Trends in Pharmacological Sciences

IS - 6

ER -

Omaveloxolone (Skyclarys^TM) for patients with Friedreich's ataxia

ASJC Scopus subject areas

Access to Document

Other files and links

The Effect Of Malaria Parasites On Dendritic Cell Metabolism (TEMPODM) (joint with University of Glasgow)

The Role of Nrf2 in the Tumour Microenvironment of IDH Wild-Type Glioma (Joint with University of Edinburgh)

The Assessment of Bioenergetic Dysfunction in Chronic Disease

Cite this

Omaveloxolone (SkyclarysTM) for patients with Friedreich's ataxia

ASJC Scopus subject areas

Access to Document

Other files and links

Projects

The Effect Of Malaria Parasites On Dendritic Cell Metabolism (TEMPODM) (joint with University of Glasgow)

The Role of Nrf2 in the Tumour Microenvironment of IDH Wild-Type Glioma (Joint with University of Edinburgh)

The Assessment of Bioenergetic Dysfunction in Chronic Disease

Cite this

Omaveloxolone (Skyclarys^TM) for patients with Friedreich's ataxia